A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in Argentina

Completed

• Conditions: Angioedemas, Hereditary

• Registration Number: NCT04955964
• Lead Sponsor: Takeda

Brief Summary

The main aim of this study is to learn about the safety profile of lanadelumab in teenagers and adults with hereditary angioedema (HAE) in Argentina as part of routine routine practice.

This study is about collecting data only. The study sponsor will not be involved in how participants are treated but will provide instructions on how the clinics will record what happens during the study. The study will collect data from the participant's medical records.

Participants do not need to visit their doctor in addition to their normal visits.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-06-30
• Study First Submitted QC: 2021-06-30
• Study First Posted: 2021-07-09
• Study Start: 2021-07-28
• Primary Completion: 2023-08-07
• Study Completion: 2023-08-07
• Status Verified: 2023-10
• Last Update Submitted: 2023-10-03
• Last Update Posted: 2023-10-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

• Participants (>=12 years) with investigator confirmed diagnosis of HAE.
• Have received at least one dose of lanadelumab according to approved indications.
• Signed the mandatory consent that has been agreed with national regulatory authorities (ANMAT) as applicable.

Read More

Exclusion Criteria

• Hypersensitivity to the active substance or to any of the excipients.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of Participants With Serious and Non-serious Adverse Events (AEs)	Baseline up to end of study (up to 24 months)	An AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. Serious AE is any untoward medical occurrence (whether considered to be related to study assigned treatment or not) that at any dose resulted in death, is life-threatening event, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital abnormality/birth defect, or was an important medical event. AEs including both serious and non-serious adverse events will be reported.
Percentage of Participants With Adverse Events of Special Interest (AESIs)	Baseline up to end of study (up to 24 months)	An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. Percentage of participants with AESIs such as hypersensitivity, immunogenicity, liver toxicity, and embryo-fetal toxicity will be reported.

Secondary Outcome Measures

Name	Time	Method
Monthly Mean Rate of Investigator Confirmed HAE Attacks Requiring Acute Treatment	At Weeks 12 and 24	HAE attack is defined as a discrete episode during which the participant progressed from no angioedema to symptoms of angioedema based on investigator judgement. In general, the event must have symptoms or signs consistent with an attack in \>=1 of the typical locations (peripheral angioedema; abdominal angioedema; laryngeal/tongue angioedema). Monthly mean rate of investigator confirmed HAE attacks requiring acute treatment with assessments at Weeks 12 and 24 will be reported.
Monthly Mean Rate of Investigator Confirmed HAE Attacks	At Weeks 12 and 24	HAE attack is defined as a discrete episode during which the participant progressed from no angioedema to symptoms of angioedema based on investigator judgement. In general, the event must have symptoms or signs consistent with an attack in greater than or equal to (\>=) 1 of the typical locations (peripheral angioedema; abdominal angioedema; laryngeal/tongue angioedema). Monthly mean rate of investigator confirmed HAE attacks with assessments at Weeks 12 and 24 will be reported.
Monthly Mean Rate of Investigator Confirmed Moderate or Severe HAE Attacks	At Weeks 12 and 24	The overall severity of attack will be determined by the investigator using following definitions: mild (transient or mild discomfort), moderate (mild to moderate limitation in activity), severe (marked limitation in activity). Monthly mean rate of investigator confirmed moderate or severe HAE attacks with assessments at Weeks 12 and 24 will be reported.
Percentage of Participants who are Attack Free	At Weeks 12 and 24	A participant will be considered as attack free during an efficacy evaluation period if the participant has no investigator-confirmed HAE attacks during treatment period. HAE attack is defined as a discrete episode during which the participant progressed from no angioedema to symptoms of angioedema based on investigator judgement. In general, the event must have symptoms or signs consistent with an attack in \>=1 of the typical locations (peripheral angioedema; abdominal angioedema; laryngeal/tongue angioedema). Percentage of participants who are attack free with assessments at 12 and 24 weeks will be reported.

Trial Locations

Locations (1)

Ic Projects Srl; 🇦🇷 Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina